Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

DRMA - Dermata Therapeutics, Inc Stock Price, Fair Value and News

$1.18-0.04 (-3.28%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

DRMA Price Action

Last 7 days

10.9%

Last 30 days

8.9%

Last 90 days

11.9%

Trailing 12 Months

197.6%

DRMA Stock Price

DRMA RSI Chart

JunJulAugSepOctNovDec2025FebMar20304050607080

DRMA Valuation

Market Cap

2.5M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

1.47

Price/Free Cashflow

-0.26

DRMA Price/Sales (Trailing)

2023AprJulOct2024AprJulOct202501020304050

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DRMA Fundamentals

DRMA Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

1.5K%

Rev. Growth (Qtr)

2.6K%

2023AprJulOct2024AprJul0500K1M1.5M

DRMA Earnings

Earnings (TTM)

-11.3M

Earnings Growth (Yr)

-84.57%

Earnings Growth (Qtr)

-12.16%

20202021202220232024-12M-10M-8M-6M-4M

DRMA Profitability

Return on Equity

-237.71%

Return on Assets

-168.53%

Free Cashflow Yield

-377.41%

DRMA Investor Care

Shares Dilution (1Y)

859.90%

Revenue Breakdown

As of: Sep 30, 2024
AprJulOct2024AprJul0500K1M1.5M
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024279.0K302.6K1.7M0
2023109.5K155.4K201.3K247.2K
202200063.6K
Get all data in R, Python etc through our Historical Stock Data APIs

About Dermata Therapeutics, Inc

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
 CEO
 WEBSITEdermatarx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES8

Dermata Therapeutics, Inc Frequently Asked Questions

What is the ticker symbol for Dermata Therapeutics, Inc? What does DRMA stand for in stocks?

DRMA is the stock ticker symbol of Dermata Therapeutics, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dermata Therapeutics, Inc (DRMA)?

As of Wed Mar 12 2025, market cap of Dermata Therapeutics, Inc is 2.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DRMA stock?

You can check DRMA's fair value in chart for subscribers.

Is Dermata Therapeutics, Inc a good stock to buy?

The fair value guage provides a quick view whether DRMA is over valued or under valued. Whether Dermata Therapeutics, Inc is cheap or expensive depends on the assumptions which impact Dermata Therapeutics, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DRMA.

What is Dermata Therapeutics, Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 12 2025, DRMA's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 1.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DRMA PE ratio will change depending on the future growth rate expectations of investors.